[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637203":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":25,"id":53,"slug":25,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":25,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of Rochester","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard-of-care Group","ACTIVE_COMPARATOR","Participants in this group will receive echocardiogram imaging before cycles 1, 5, 9, and 13 of trastuzumab (or every 3 months) and another echocardiogram after completion of trastuzumab (within 100 days after completion of HER2-TT).",[13],"Procedure: Echocardiogram",{"label":15,"type":16,"description":17,"interventionNames":18},"Judicious-imaging Group","EXPERIMENTAL","The Judicious Imaging Group will get split into two separate subgroups, intermediate-risk or low-risk, depending on their risk of heart failure, which will determine how many echocardiograms they will receive. The low-risk subgroup will get an echocardiogram once every 6 months (before cycles 1 and 9 and after the completion of trastuzumab). The intermediate-risk subgroup will get an echocardiogram approximately once every 4 months (before cycles 1, 6, and 12 and after completion of trastuzumab).",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Echocardiogram","12-lead echocardiogram",[15,9],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Kaily LaForce","CONTACT","585-274-2808","kaily_laforce@urmc.rochester.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Wilmot Cancer Center","RECRUITING","Rochester","New York","14642","United States",{"type":41,"coordinates":42},"Point",[43,44],-77.61556,43.15478,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":25,"phoneExt":25,"email":25},"Farhan Bajwa, MD, FACC","PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Farhan Bajwa","Assistant Professor","100637203",false,"NCT07630402","Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer","Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer","POCEB","Inclusion Criteria:\n\n* Female sex, age 18-79 years.\n* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT\n* Baseline LVEF ≥ 55 % by 2-D echocardiography.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Prior HF, myocardial infarction, or cardiomyopathy.\n* Atrial fibrillation or significant valvular heart disease.\n* Cumulative anthracycline dose ≥ 250 mg\u002Fm².\n* Pregnancy or lactation.\n* Inability to comply with study procedures.","FEMALE","18 Years","79 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"NA","The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).",[71],"Breast Cancer With Low to Intermediate HER2 Expression","2026-06-01",{"date":74,"type":75},"2026-06-05","ACTUAL",{"date":77,"type":75},"2025-11-17",{"date":79,"type":65},"2031-06-30",{"name":5,"class":6},1]